Home » Newsletters » BioWorld Science

BioWorld Science

May 17, 2010

View Archived Issues

Endece's novel ER agonists block chromosome replication and show antitumor activity in vivo

Actelion claims novel calcium channel blockers

INS-115644 reduces IOP in glaucoma, ocular hypertension patients

Novel antifungal agents identified by Indian scientists

Bristol-Myers Squibb claims novel MCH-R1 antagonists

Basilea Pharmaceutica's novel tubulin polymerization inhibitors show promising preclinical activity

Novel anti-PLGF murine monoclonal antibody P-16 displays potent antitumor activity in vivo

Presidio reports preclinical data on its novel HCV NS5A inhibitor PPI-461

VAX-102 increases immune response to trivalent influenza vaccine

Promising phase II data on JX-594 in HCC support phase III evaluation

Chimerix initiates first-in-human phase I study of CMX-157

Array BioPharma discloses novel Trk kinase inhibitors

DMC recommends continuation of phase III ThermoDox HEAT study

Merck & Co. identifies novel orexin receptor antagonists

Repligen files IND with FDA for Friedreich's ataxia drug

Meda acquires European rights from Graceway to new imiquimod formulation for AK

Rexahn to move forward with phase IIb trial of Zoraxel for ED

Octapharma launches Wilate for von Willebrand disease

FDA assigns November 4, 2010 action date for Cadence's Ofirmev NDA

Roche to begin study of TB-403 in patients with colorectal and ovarian cancer

Amgen submits BLA for denosumab for skeletal-related events in cancer patients

SRI International's SR-16388 has promise for multiple myeloma

Astellas to acquire OSI Pharmaceuticals

FDA recommends resumption of use of Rotarix

Lundbeck announces results of pivotal Japanese study of escitalopram

SciClone provides update on clinical program for SCV-07 in oral mucositis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...